<VariationArchive VariationID="2422279" VariationName="NC_000003.11:g.(?_15512023)_(15687154_?)del" VariationType="Deletion" Accession="VCV002422279" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1942313" VariationID="2422279">
      <GeneList>
        <Gene Symbol="BTD" FullName="biotinidase" GeneID="686" HGNC_ID="HGNC:1122" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>3p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="15601361" stop="15722516" display_start="15601361" display_stop="15722516" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="15643254" stop="15687324" display_start="15643254" display_stop="15687324" Strand="+" />
          </Location>
          <OMIM>609019</OMIM>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="COLQ" FullName="collagen like tail subunit of asymmetric acetylcholinesterase" GeneID="8292" HGNC_ID="HGNC:2226" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>3p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="15450133" stop="15521706" display_start="15450133" display_stop="15521706" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="15491639" stop="15563257" display_start="15491639" display_stop="15563257" Strand="-" />
          </Location>
          <OMIM>603033</OMIM>
        </Gene>
        <Gene Symbol="HACL1" FullName="2-hydroxyacyl-CoA lyase 1" GeneID="26061" HGNC_ID="HGNC:17856" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>3p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="15560699" stop="15601569" display_start="15560699" display_stop="15601569" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="15602238" stop="15643129" display_start="15602238" display_stop="15643129" Strand="-" />
          </Location>
          <OMIM>604300</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000003.11:g.(?_15512023)_(15687154_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p25.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" innerStart="15512023" innerStop="15687154" display_start="15512023" display_stop="15687154" variantLength="175132" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.(?_15512023)_(15687154_?)del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.(?_15512023)_(15687154_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000003.11:g.(?_15512023)_(15687154_?)del AND Biotinidase deficiency" Accession="RCV003119225" Version="4">
        <ClassifiedConditionList TraitSetID="482">
          <ClassifiedCondition DB="MedGen" ID="C0220754">Biotinidase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-07-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-07-08" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20083419</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="482" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1025" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">BTD deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Late-onset biotin-responsive multiple carboxylase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Biotinidase deficiency</ElementValue>
                <XRef ID="Biotinidase+Deficiency/846" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009665" DB="MONDO" />
                <XRef ID="8808004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Biotin deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">If untreated, young children with profound biotinidase deficiency usually exhibit neurologic abnormalities including seizures, hypotonia, ataxia, developmental delay, vision problems, hearing loss, and cutaneous abnormalities (e.g., alopecia, skin rash, candidiasis). Older children and adolescents with profound biotinidase deficiency often exhibit motor limb weakness, spastic paresis, and decreased visual acuity. Once vision problems, hearing loss, and developmental delay occur, they are usually irreversible, even with biotin therapy. Individuals with partial biotinidase deficiency may have hypotonia, skin rash, and hair loss, particularly during times of stress.</Attribute>
                <XRef ID="NBK1322" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="894" />
                <XRef ID="894" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301497</ID>
                <ID Source="BookShelf">NBK1322</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2010">
                <URL>https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Biotinidase.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Biotinidase Deficiency</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2006">
                <URL>https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Visio-Biotinidase.pdf</URL>
                <CitationText>American College of Medical Genetics Algorithm, Biotinidase Deficiency, 2006</CitationText>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2012">
                <ID Source="PubMed">22378278</ID>
              </Citation>
              <Citation Type="general" Abbrev="CDC, 2012">
                <ID Source="PubMed">22475884</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2017">
                <ID Source="PubMed">28682309</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Biotinidase-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Newborn Screening ACT Sheet, [Absent/ Reduced Biotinidase Activity], Biotinidase Deficiency</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Biotinidase-Deficiency.aspx</URL>
                <CitationText>American College of Medical Genetics Algorithm, Biotinidase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Biotinidase-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Biotinidase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C5-OH Acylcarnitine, Organic Acidemias, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Organic Acidemias: Elevated C5-OH, 2022</CitationText>
              </Citation>
              <XRef ID="79241" DB="Orphanet" />
              <XRef ID="C0220754" DB="MedGen" />
              <XRef ID="MONDO:0009665" DB="MONDO" />
              <XRef Type="MIM" ID="253260" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7071044" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_000060.3_3_Deletion (entire coding sequence)|MedGen:C0220754" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003790190" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-07-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20083419</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with BTD-related conditions. A gross deletion of the genomic region encompassing the full coding sequence of the BTD gene has been identified. Loss-of-function variants in BTD are known to be pathogenic (PMID: 20083419). The boundaries of this event are unknown as they extend beyond the assayed region for this gene and therefore may encompass additional genes.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BTD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.(?_15512023)_(15687154_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0220754" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7071044" TraitType="Disease" MappingType="XRef" MappingValue="C0220754" MappingRef="MedGen">
        <MedGen CUI="C0220754" Name="Biotinidase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

